Cryo-Cell International Inc. Common Stock (CCEL)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look first for a durable business and a margin of safety. Cryo-Cell stores cord blood and tissue, a niche healthcare service with 72 employees. The filed numbers show a tiny, uneven enterprise: fiscal 2025 revenue was $31.6 million, down from $32.0 million in fiscal 2024, and the company swung to a net loss of $2.4 million, or $0.30 per diluted share, after earning $402,095 in fiscal 2024. That fits the computed Lynch category of TURNAROUND. More recently, fiscal Q3 2026 ended 2026-08-31 showed revenue of $7.8 million, net income of $1.3 million, and diluted EPS of $0.16; fiscal Q2 2026 earned $554,586, and fiscal Q1 2026 earned $47,108. So the latest filed quarters are profitable, which is encouraging but not yet a full-year trend. The balance-sheet and valuation signals are mixed to poor: FairStock's Piotroski F-Score is 7/9, but its Altman Z-Score is -0.51, EV/EBITDA is 310.35, and the P/E is -17.92 at the 2026-10-13 close of $4.30. TTM free cash flow of $4.3 million gives a 12.3% FCF yield on a $34.7 million market cap, which is the main attraction. ROCE of 0.19% and a FairStock Score of 26/100 argue that quality is unproven. I cannot identify a durable moat from these figures, only a possible turnaround with cash generation. Price may look cheap on cash flow but expensive and risky on earnings and financial strength.

In plain English: Cryo-Cell International stores umbilical cord blood and tissue for families. The business looks weak overall: annual revenue has been flat to down, and the latest full year lost money, though recent quarters showed small profits and positive cash flow. At $4.30, the stock looks cheap compared with its cash flow but risky compared with its earnings and balance-sheet signals.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-08-31) · fiscal Q2 2026 10-Q (period ended 2026-05-31) · fiscal Q1 2026 10-Q (period ended 2026-02-28) · fiscal Q3 2025 10-Q (period ended 2025-08-31) · FY2025 10-K (period ended 2025-11-30) · FY2024 10-K (period ended 2024-11-30) · FY2023 10-K (period ended 2023-11-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer